November 30, 2016 - By Marie Mckinney
The well-informed person Dennis Selkoe who is director of Prothena Corp Plc sold 5,000 shares of the ‘s company valued at near $312,118 US Dollars which is based on a stock price of $62.4 for each one share. This sale was made on November 30, 2016. A legal form that was filed with the U.S. SEC and obtainable online here, reveals an extra information for the sale. Now, he holds 4,208 shares or 0.01% of the company’s market cap (share price times the number of shares outstanding).
Out of 5 analysts covering Prothena Corp (NASDAQ:PRTA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $95 is the highest target while $60 is the lowest. The $75.33 average target is 27.46% above today’s ($59.1) stock price. Prothena Corp has been the topic of 10 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Thursday, November 19 by RBC Capital Markets. The rating was initiated by Deutsche Bank on Thursday, November 3 with “Buy”. The company was maintained on Friday, February 19 by Wedbush. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Outperform” rating given on Tuesday, August 4 by Wedbush. The firm has “Overweight” rating by Barclays Capital given on Thursday, August 4. The rating was initiated by Credit Suisse with “Outperform” on Thursday, January 21. On Friday, May 13 the stock rating was initiated by Barclays Capital with “Overweight”.
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.19, from 1.04 in 2016Q1. The ratio increased, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
Loring Wolcott & Coolidge Fiduciary Limited Liability Partnership Ma holds 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 22 shares. Prudential Fincl Inc has 66,770 shares for 0% of their US portfolio. Bancshares Of Mellon last reported 162,670 shares in the company. Employees Retirement Association Of Colorado last reported 0% of its portfolio in the stock. The Illinois-based Ubs Oconnor Ltd Liability Corporation has invested 0% in Prothena Corporation PLC (NASDAQ:PRTA). Mycio Wealth Partners Limited Liability owns 289 shares or 0% of their US portfolio. Smith Asset Grp Inc Limited Partnership holds 0.01% or 7,150 shares in its portfolio. Whittier Trust Company Of Nevada has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Cornerstone Advsrs Incorporated reported 130 shares or 0.01% of all its holdings. Schwab Charles Investment Mgmt has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Dupont Capital Mngmt owns 14,475 shares or 0.01% of their US portfolio. Pinnacle Associate owns 436,417 shares or 0.33% of their US portfolio. Deutsche Fincl Bank Ag has 0% invested in the company for 73,094 shares. Moreover, Teachers has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 78,083 shares. Thompson Siegel Walmsley Ltd Llc reported 21 shares or 0% of all its holdings.
Insider Transactions: Since July 20, 2016, the stock had 0 insider purchases, and 8 insider sales for $3.70 million net activity. HOMAN ARTHUR W sold $488,813 worth of stock. Kinney Gene G. had sold 8,548 shares worth $472,905 on Wednesday, November 9. Shares for $271,173 were sold by Walker Karin L. Selkoe Dennis J. sold 5,000 shares worth $273,076.
About 315,001 shares traded hands. Prothena Corporation PLC (NASDAQ:PRTA) has risen 36.49% since April 27, 2016 and is uptrending. It has outperformed by 31.26% the S&P500.
Prothena Corporation Public Limited Company is a global biotechnology company. The company has a market cap of $2.03 billion. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It currently has negative earnings. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”
Analysts await Prothena Corporation PLC (NASDAQ:PRTA) to report earnings on February, 16. They expect $-1.21 EPS, down 59.21% or $0.45 from last year’s $-0.76 per share. After $-1.26 actual EPS reported by Prothena Corporation PLC for the previous quarter, Wall Street now forecasts -3.97% EPS growth.
More news for Prothena Corporation PLC (NASDAQ:PRTA) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on April 02, 2013. Fool.com‘s article titled: “Why Prothena Corporation Plc is Soaring Higher Today” and published on March 20, 2015 is yet another important article.
Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.